Nina Otinashvili
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nina Otinashvili has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Abhay Krishnan Iyer
School of Psychology, University of Wolverhampton, Wolverhampton, UK
1 shared publication - Azada Ismayilova
Faculty of Medicine, Azerbaijan Medical University, Baku, Azerbaijan
1 shared publication - Jeremiah Hilkiah Wijaya
School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia
1 shared publication - Made Agus Mahendra Inggas
Department of Neurosurgery, Universitas Pelita Harapan, Tangerang, Indonesia
1 shared publication - Marie Gadaevi
Department of Medicine, Tbilisi State Medical University, Tbilisi, Georgia
1 shared publication Nihar Upadhyay
Department of Medicine, GMERS Medical College and Hospital, Gotri, India
1 shared publication
Latest Publications
- Open Access
- 5 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-8
The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies. We aim to consolidate existing evidence related to the safety and efficacy of TMZ as adjuvant therapy to radiotherapy (RT). Various electronic platforms were used to conduct a systematic literature review, including PubMed, Europe PMC, SCOPUS, and clinicaltrials.gov. The approach aimed to identify all pertinent studies published up to July 25, 2024. The search incorporated terms such as “glioblastoma,” “temozolomide,” “monotherapy,” and “adjuvant” alongside relevant Medical Subject Headings (MeSH). The key metrics were overall and progression-free survival, while secondary measures concentrated on treatment-related adverse effects, notably hematological issues like anemia, leukopenia, thrombocytopenia, and neutropenia. The overall effect estimates from the forest plots show significant differences favoring TMZ + RT over RT alone. The HR for overall survival is 0.64 (95% CI: 0.58, 0.71), showing a considerable improvement with TMZ + RT. Progression-free survival shows a HR of 0.51 (95% CI: 0.45, 0.58), also demonstrating a significant benefit for TMZ + RT. Combining TMZ with RT generally leads to better overall and progression-free survival outcomes compared to RT alone. However, the two treatment groups have similar toxicity.
- 5 March 2025
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-8
Open AccessThe role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.
The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies. We aim to consolidate existing evidence related to the safety and efficacy of TMZ as adjuvant therapy to radiotherapy (RT). Various electronic platforms were used to conduct a systematic literature review, including PubMed, Europe PMC, SCOPUS, and clinicaltrials.gov. The approach aimed to identify all pertinent studies published up to July 25, 2024. The search incorporated terms such as “glioblastoma,” “temozolomide,” “monotherapy,” and “adjuvant” alongside relevant Medical Subject Headings (MeSH). The key metrics were overall and progression-free survival, while secondary measures concentrated on treatment-related adverse effects, notably hematological issues like anemia, leukopenia, thrombocytopenia, and neutropenia. The overall effect estimates from the forest plots show significant differences favoring TMZ + RT over RT alone. The HR for overall survival is 0.64 (95% CI: 0.58, 0.71), showing a considerable improvement with TMZ + RT. Progression-free survival shows a HR of 0.51 (95% CI: 0.45, 0.58), also demonstrating a significant benefit for TMZ + RT. Combining TMZ with RT generally leads to better overall and progression-free survival outcomes compared to RT alone. However, the two treatment groups have similar toxicity.